Viking Therapeutics (VKTX) Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214

Go back to Viking Therapeutics (VKTX) Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214
ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) Delayed: 6.52 -0.02 (0.31%)
Previous Close $6.54    52 Week High $5.17 
Open $6.48    52 Week Low $0.94 
Day High $6.70    P/E N/A 
Day Low $6.44    EPS $0.00 
Volume 364,002